Quoin Pharmaceuticals Ltd DRC
$ 4.24
1.92%
17 Jul - close price
- Market Cap 8,515,700 USD
- Current Price $ 4.24
- High / Low $ 4.36 / 4.10
- Stock P/E N/A
- Book Value 4.47
- EPS -10.07
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -2.31 %
- 52 Week High 23.50
- 52 Week Low 3.25
About
Quoin Pharmaceuticals Ltd (QNRX) is an innovative biotechnology firm dedicated to developing cutting-edge therapeutics for rare diseases, addressing significant unmet medical needs in the healthcare landscape. Leveraging advanced drug delivery technologies, Quoin enhances the efficacy and safety of its treatment pipeline, thereby positioning itself for impactful clinical advancements. The company emphasizes strategic collaborations and groundbreaking research initiatives, aiming to create substantial value for both patients and investors while establishing a formidable presence in the specialty pharmaceuticals sector.
Analyst Target Price
$21.40
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-26 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-08 | 2023-08-02 |
| Reported EPS | -1.77 | -1.74 | -6.7 | -6.28 | -6.5 | -0.2781 | -16.45 | -13.67 | -38.62 | -2.08 | -68.25 | -73.48 |
| Estimated EPS | -2.26 | -4.02 | -1.92 | -6.83 | -4.2 | -0.43 | -15.4 | -20.3 | -14.35 | -2.31 | -95.32 | -96.6 |
| Surprise | 0.49 | 2.28 | -4.78 | 0.55 | -2.3 | 0.1519 | -1.05 | 6.63 | -24.27 | 0.23 | 27.07 | 23.12 |
| Surprise Percentage | 21.6814% | 56.7164% | -248.9583% | 8.0527% | -54.7619% | 35.3256% | -6.8182% | 32.6601% | -169.1289% | 9.9567% | 28.3991% | 23.9337% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.83 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QNRX
2026-07-16 23:40:13
This page provides financial information for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is closed with no current trades. It also details that select market data is provided by ICE Data Services and reference data by FactSet.
2026-07-16 20:40:22
This article displays the "Enterprise value to EBIT forward" for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades and provides a link to the financial data for the company. The rest of the content is navigational and footer information from the TradingView platform.
2026-07-16 19:11:14
This article provides access to the Annual Report to Security Holders (ARS) for Quoin Pharmaceuticals. The report is a crucial document for investors and stakeholders, offering a comprehensive overview of the company's financial performance and operational activities over the past year.
2026-07-16 11:11:14
Quoin Pharmaceuticals will hold its 2026 Annual General Meeting on August 20, 2026, where shareholders will vote on five key proposals, including the election of seven directors, an advisory "say-on-pay" for executive compensation, changes to director compensation, and changes to 401(k) matching contributions. The board recommends voting "FOR" all proposals. The proxy statement also details executive compensation, related party transactions, and beneficial ownership information.
2026-07-16 11:11:14
Insiders at Quoin Pharmaceuticals who purchased US$128.6k worth of stock at an average price of US$8.49 over the past year have seen their investment decrease to US$63.8k after an 11% price decline. The largest insider purchase was made by Independent Director Dennis Langer at a price higher than the current market value, suggesting prior optimism. While recent insider transactions have been absent, the analysis suggests a generally heartening, though not overwhelmingly strong, alignment of insider ownership with shareholder interests.
2026-07-10 09:10:42
Quoin Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This marks the first formal clinical study for PSS, a condition with no approved treatments. The FDA expressed no safety concerns regarding the study design or dosing duration, and QRX003 is also being developed for Netherton Syndrome and other orphan skin diseases.
